Vitamin D supplementation during pregnancy: Effect on the neonatal immune system in a randomized controlled trial

Background

Programming of the immune system during fetal development can influence asthma-related risk factors and outcomes in later life. Vitamin D is a well-recognized immune modulator, and deficiency of this nutrient during pregnancy is hypothesized to influence disease development in offspring.

Objective

We sought to investigate the effect on neonatal immunity of maternal supplementation with 4400 IU/d vitamin D3during the second and third trimesters of pregnancy by using a subset of cord blood samples from a randomized, double-blind, placebo-controlled clinical trial (the Vitamin D Antenatal Asthma Reduction Trial).

Methods

Cord blood samples from neonates born to mothers supplemented with 4400 IU/d (n = 26) or 400 IU/d (n = 25) of vitamin D3 were analyzed for immune cell composition by flow cytometry, Toll-like receptor (TLR) expression by quantitative PCR, and cytokine secretion after stimulation with mitogenic, TLR, and T-cell stimuli by cytometric bead array. Responsiveness to the glucocorticoid dexamethasone was determined.

Results

Supplementation of mothers with 4400 IU of vitamin D3 resulted in an enhanced broad-spectrum proinflammatory cytokine response of cord blood mononuclear cells to innate and mitogenic stimuli (P = .0009), with an average 1.7- to 2.1-fold increase in levels of several proinflammatory cytokines (GM-CSF, IFN-γ, IL-1β, IL-6, and IL-8) across stimuli, a higher gene expression level of TLR2 (P = .02) and TLR9 (P = .02), a greater than 4-fold increase in IL-17A (P = .03) production after polyclonal T-cell stimulation, and an enhanced IL-10 response of cord blood mononuclear cells to dexamethasone treatment in culture (P = .018).

Conclusion

Vitamin D exposure during fetal development influences the immune system of the neonate, which can contribute to protection from asthma-related, including infectious, outcomes in early life.

Full Text

PDF (865 KB)

 

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @Aller_MD: “JAK Inhibitors Showing Promise for Many Skin Problems Conditions ranging from alopecia to vitiligo” https://t.co/mSR0or0JM5
6hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: Carina Venter PhD RD on Twitter: "A few months ago Cat’s in the Crad… https://t.co/hSf86Y42Qo, see more https://t.…
6hreplyretweetfavorite
Interasma RT @Aller_MD: “Mechanistic insights on topical tacrolimus for the treatment of atopic dermatitis” https://t.co/YFs34eAADf https://t.co/UZMa
6hreplyretweetfavorite
Interasma RT @Aller_MD: Upper and lower airway remodelling mechanisms in #asthma, #allergic rhinitis and chronic #rhinosinusitis: the one airway conc…
6hreplyretweetfavorite
Interasma RT @Aller_MD: Hot Topics: Recent Developments in Dermatologic Therapies https://t.co/w5mnT5B566 https://t.co/Vj5jJmgoO6
11hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma